Soligenix, Inc. (SNGX)
SNGX Stock Price Chart
Explore Soligenix, Inc. interactive price chart. Choose custom timeframes to analyze SNGX price movements and trends.
SNGX Company Profile
Discover essential business fundamentals and corporate details for Soligenix, Inc. (SNGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Apr 1994
Employees
14.00
Website
https://www.soligenix.comCEO
Christopher J. Schaber
Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
SNGX Financial Timeline
Browse a chronological timeline of Soligenix, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.82.
Earnings released on 14 Aug 2025
EPS came in at -$0.82 falling short of the estimated -$0.79 by -3.80%.
Earnings released on 9 May 2025
EPS came in at -$1.06 falling short of the estimated -$0.67 by -58.21%.
Earnings released on 21 Mar 2025
EPS came in at -$1.14 falling short of the estimated -$0.95 by -20.00%, while revenue for the quarter reached $6.35K , missing expectations by -96.82%.
Earnings released on 8 Nov 2024
EPS came in at -$0.78 surpassing the estimated -$1.09 by +28.44%.
Earnings released on 9 Aug 2024
EPS came in at -$1.31 surpassing the estimated -$2.11 by +37.91%, while revenue for the quarter reached $2.34K , missing expectations by -98.83%.
Stock split effective on 6 Jun 2024
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2024
EPS came in at -$2.88 surpassing the estimated -$3.20 by +10.00%, while revenue for the quarter reached $117.03K , missing expectations by -41.49%.
Earnings released on 15 Mar 2024
EPS came in at -$2.56 surpassing the estimated -$3.04 by +15.79%, while revenue for the quarter reached $244.81K , beating expectations by +22.41%.
Earnings released on 13 Nov 2023
EPS came in at -$2.56 surpassing the estimated -$7.04 by +63.64%, while revenue for the quarter reached $130.44K , missing expectations by -34.78%.
Earnings released on 21 Aug 2023
EPS came in at -$2.72 surpassing the estimated -$7.84 by +65.31%, while revenue for the quarter reached $206.93K , beating expectations by +3.46%.
Earnings released on 15 May 2023
EPS came in at -$5.76 surpassing the estimated -$20.00 by +71.20%, while revenue for the quarter reached $257.18K , beating expectations by +28.59%.
Earnings released on 31 Mar 2023
EPS came in at -$4.58 falling short of the estimated -$1.12 by -308.93%, while revenue for the quarter reached $366.07K , beating expectations by +83.03%.
Stock split effective on 10 Feb 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2022
EPS came in at -$19.19 matching the estimated -$19.19, while revenue for the quarter reached $166.14K , missing expectations by -16.93%.
Earnings released on 12 Aug 2022
EPS came in at -$14.39 surpassing the estimated -$16.79 by +14.29%, while revenue for the quarter reached $228.64K , beating expectations by +14.32%.
Earnings released on 13 May 2022
EPS came in at -$23.99 falling short of the estimated -$14.39 by -66.71%, while revenue for the quarter reached $188.06K , beating expectations by +88.06%.
Earnings released on 29 Mar 2022
EPS came in at -$26.39 falling short of the estimated -$19.19 by -37.52%, while revenue for the quarter reached $275.65K , beating expectations by +37.83%.
Earnings released on 12 Nov 2021
EPS came in at -$21.59 surpassing the estimated -$31.18 by +30.76%, while revenue for the quarter reached $186.20K , missing expectations by -55.67%.
Earnings released on 13 Aug 2021
EPS came in at -$11.99 surpassing the estimated -$26.39 by +54.57%, while revenue for the quarter reached $214.82K , missing expectations by -60.22%.
Earnings released on 17 May 2021
EPS came in at -$14.39 surpassing the estimated -$26.39 by +45.47%, while revenue for the quarter reached $147.59K , missing expectations by -73.64%.
Earnings released on 30 Mar 2021
EPS came in at -$45.58 falling short of the estimated -$21.59 by -111.12%, while revenue for the quarter reached $320.79K .
Earnings released on 12 Nov 2020
EPS came in at -$14.39 surpassing the estimated -$23.99 by +40.02%, while revenue for the quarter reached $608.81K , missing expectations by -23.61%.
SNGX Stock Performance
Access detailed SNGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.